

**DRUG NAME: Azacitidine****SYNONYM(S):** ladaKamycin<sup>1</sup>**COMMON TRADE NAME(S):** VIDAZA®**CLASSIFICATION:** miscellaneous*Special pediatric considerations are noted when applicable, otherwise adult provisions apply.***MECHANISM OF ACTION:**

Azacitidine is a synthetic pyrimidine nucleoside analog of cytidine. Azacitidine appears to exert its antineoplastic effect by multiple mechanisms, including a direct cytotoxic effect on abnormal hematopoietic cells in the bone marrow through incorporation into DNA and RNA, and an inhibition of DNA methyltransferase, causing hypomethylation of DNA. Hypomethylation may restore normal function to genes critical for differentiation and proliferation. Nonproliferating cells are relatively insensitive to azacitidine.<sup>1,2</sup> The relative importance of DNA hypomethylation versus cytotoxicity mechanism has not been established.<sup>2</sup>

**PHARMACOKINETICS:**

Absorption	rapid following subcutaneous injection (89% bioavailability relative to IV)	
Distribution	peak plasma concentrations occurring at 0.5 h	
	cross blood brain barrier?	no <sup>3</sup>
	volume of distribution	76 ± 26 L (IV); not calculated for SC
	plasma protein binding	no information found
Metabolism	by spontaneous hydrolysis (primarily) and deamination by cytidine deaminase; several metabolites (unnamed) <sup>3</sup>	
	active metabolite(s)	no information found
	inactive metabolite(s)	no information found
Excretion	primarily in urine for parent compound and metabolites	
	urine	50-85%
	feces	<1%
	terminal half life	41 ± 8 min (SC); 22 ± 1 min (IV)
	clearance	167 ± 49 L/h (SC); 147 ± 47 L/h (IV)
Elderly	no overall difference in safety and effectiveness	

Adapted from standard reference<sup>4</sup> unless specified otherwise.**USES:****Primary uses:**

\*Myelodysplastic syndromes

\*Leukemia, acute myeloid

\*Health Canada approved indication

**Other uses:**

**SPECIAL PRECAUTIONS:****Contraindications:**

- advanced malignant hepatic tumours<sup>2</sup>

**Caution:**

- tumour lysis syndrome has been reported; patients with high tumour burden prior to treatment are at risk<sup>4</sup>

**Carcinogenicity:** In animal studies, azacitidine has shown carcinogenic potential, inducing tumours of the hematopoietic system, and increasing the incidence of tumours in the lymphoreticular system, lung, mammary gland, skin, and testes.<sup>2</sup>

**Mutagenicity:** Mutagenic in Ames test and other *in vitro* bacterial microsome tests. Azacitidine is clastogenic in mammalian *in vitro* chromosome tests.<sup>4</sup>

**Fertility:** In animal studies, azacitidine has produced adverse effects on male reproduction and fertility (i.e., decreased testes and epididymides weights as well as decreased sperm count) and decreased pregnancy rates.<sup>4</sup>

**Pregnancy:** FDA Pregnancy Category D.<sup>3</sup> There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). Fetal deaths and multiple fetal abnormalities, including CNS and limb anomalies, were observed in animal studies. Women of childbearing potential should be advised to use effective contraception during and for up to three months following treatment. Males should be advised to avoid fathering a child during and for six months following treatment.<sup>2</sup>

**Breastfeeding** is not recommended due to the potential secretion into breast milk.

**SIDE EFFECTS:**

The table includes adverse events that presented during drug treatment but may not necessarily have a causal relationship with the drug. Because clinical trials are conducted under very specific conditions, the adverse event rates observed may not reflect the rates observed in clinical practice. Adverse events are generally included if they were reported in more than 1% of patients in the product monograph or pivotal trials, and/or determined to be clinically important.<sup>5,6</sup>

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in <b>bold, italics</b>	
blood and lymphatic system/ febrile neutropenia (see paragraph following <b>Side Effects</b> table)	<b><i>anemia</i></b> (51-70%, severe 14%); mean time to nadir is 15-16 days <sup>7</sup>
	febrile neutropenia (14-16%, severe 13%)
	leukopenia (18-48%, severe 15%)
	<b><i>neutropenia</i></b> (32-66%, severe 61%); mean time to nadir is 15-16 days <sup>7</sup>
	pancytopenia (<10%) <sup>4</sup>
	<b><i>thrombocytopenia</i></b> (66-70%; severe 58%); mean time to nadir is 15-16 days <sup>7</sup>
cardiac	atrial fibrillation (<1%)
	congestive heart failure (<1%)
	pericardial effusion (<1%)
eye	conjunctival hemorrhage (1-10%)
gastrointestinal	<b><i>emetogenic potential: low-moderate</i></b> <sup>8</sup>

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in <b>bold, italics</b>	
	abdominal pain, tenderness (12-13%, severe 4%)
	colitis (<1%)
	<b>constipation</b> (34-50%, severe 1%); possibly more pronounced in cycles 1-2; incidence may increase with higher doses
	diarrhea (6-36%); incidence may increase with higher doses
	dyspepsia (6%)
	gastrointestinal hemorrhage (<10%) <sup>4</sup>
	gingival bleeding (10%)
	hemorrhoidal hemorrhage (<10%) <sup>4</sup>
	mouth hemorrhage (5%)
	<b>nausea</b> (48-71%, severe 2%); possibly more pronounced in cycles 1-2; incidence may increase with higher doses
	pancreatitis (<1%)
	stomatitis (8%)
	<b>vomiting</b> (27-54%, severe 0%); possibly more pronounced in cycles 1-2; incidence may increase with higher doses
general disorders and administration site conditions	<i>extravasation hazard: irritant</i> <sup>9</sup>
	fatigue (24%, severe 3%)
	<b>injection site bruising</b> (5-14%), <b>erythema</b> (35-43%) and <b>pain</b> (19-23%); possibly more pronounced in cycles 1-2; incidence may increase with higher doses
	injection site necrosis <sup>4</sup> (<1%)
	<b>injection site reactions:</b> hematoma (6%); induration, granuloma (10%); pigmentation changes (5%), pruritus (7%), swelling (5%), and rash (5%)
	malaise (11%)
	peripheral edema (<1%)
	<b>pyrexia</b> (30-52%, severe 5%)
hepatobiliary	ascites (<1%)
	hepatitis, hepatic failure (<1%)
	jaundice (<1%)
immune system	hypersensitivity reaction (<1%)
infections and infestations	neutropenic sepsis (<2%)
	pneumonia (4-11%)
	rhinitis (6%)
	upper respiratory tract infection (9-15%, severe 2%)
	urinary tract infection (9%, severe 2%)
injury, poisoning, and procedural complications	post procedural hemorrhage (6%)
investigations	AST, ALT elevation <sup>4</sup> (<1%)
	blood creatinine elevation <sup>4</sup> (<1%)

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in <b>bold, italics</b>	
	hyperbilirubinemia (<1%)
	weight decrease (8%, severe 1%)
metabolism and nutrition	<b>anorexia</b> (21%)
	dehydration <sup>4</sup> (<1%)
	hyperglycemia <sup>4</sup> (<1%)
	hypokalemia (6%, severe 2%); possibly more pronounced in cycles 1-2
	hyponatremia <sup>4</sup> (<1%)
	tumour lysis syndrome <sup>4</sup> (<1%)
musculoskeletal and connective tissue	<b>arthralgias, myalgias</b> (16-22%)
	chest pain, chest wall pain (5-16%)
nervous system	cerebral hemorrhage (2%)
	convulsion <sup>4</sup> (<1%)
	<b>dizziness</b> (19%); possibly more pronounced in cycles 1-2
	<b>headache</b> (22%)
	lethargy (7-8%)
psychiatric	anxiety (5-13%); possibly more pronounced in cycles 1-2
	confusion (1-10%)
	insomnia (9-11%); possibly more pronounced in cycles 1-2
renal and urinary	hematuria (6%, severe 2%)
	renal failure <sup>4</sup> (<1%); see paragraph following <b>Side Effects</b> table
respiratory, thoracic and mediastinal	<b>dyspnea</b> (15-30%, severe 3%)
	dyspnea, exertional (5%)
	interstitial lung disease <sup>4</sup> (<1%)
	pharyngolaryngeal pain (6%)
	pulmonary embolism <sup>4</sup> (<1%)
	respiratory distress syndrome <sup>4</sup> (<1%)
skin and subcutaneous tissue	alopecia (<10%) <sup>4</sup>
	dry skin (5%)
	erythema (7-17%)
	leukocytoclastic vasculitis <sup>4</sup> (<1%)
	petechiae, ecchymosis (11-31%, severe 1%); possibly more pronounced in cycles 1-2
	pruritus (12%)
	rash (10-14%)
	Sweet's syndrome <sup>4</sup> (<1%)
	urticaria (6%)
vascular	hematoma (9%)

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in <b>bold, italics</b>	
	hypertension (9%, severe 1%)
	hypotension (7%)

Adapted from standard reference<sup>2</sup> unless specified otherwise.

**Hematologic toxicity** (i.e., anemia, neutropenia, leukopenia, and thrombocytopenia) is associated with azacitidine therapy, particularly during the first two cycles and less frequently thereafter.<sup>4,10</sup> Incidence also tends to increase with higher doses.<sup>4</sup> Mean time to nadir is 15-16 days in all cycles.<sup>7</sup> Consider treatment delay or dose reduction for hematologic toxicity depending on nadir values and length of time until recovery.<sup>4</sup>

**Renal abnormalities** ranging from elevated serum creatinine to renal failure and death have been reported with intravenous azacitidine in combination with other chemotherapy. Severe renal tubular dysfunction may manifest as hypophosphatemia, hypokalemia, or hyponatremia, with or without increases in serum creatinine and blood urea nitrogen (BUN). Renal tubular acidosis (serum bicarbonate <20 mmol/L, serum potassium <3 mmol/L, and alkaline urine), although rare, has also been reported. Monitor serum electrolytes, bicarbonate, creatinine, and BUN during treatment. Consider dose reduction or treatment delays for unexplained reductions in serum bicarbonate or elevations in serum creatinine or BUN during treatment as suggested below:

- for serum bicarbonate <20 mmol/L: consider 50% dose reduction for next cycle;
- for serum creatinine or BUN  $\geq$  2 fold above baseline or ULN: consider treatment delay until values return to normal or baseline, then 50% dose reduction for next cycle.

Monitor for increased toxicity in patients with renal impairment as azacitidine and its metabolites are primarily excreted through the kidney.<sup>4</sup>

**INTERACTIONS:** No information found; it is considered unlikely that azacitidine will have clinically significant inhibitory or inductive effects on cytochrome P450 enzymes or be affected by CYP inhibitors or inducers.<sup>2</sup>

### SUPPLY AND STORAGE:

**Injection:** Celgene Inc. supplies azacitidine as a sterile lyophilized powder for reconstitution in 100 mg single-use vials. Store at room temperature.<sup>4</sup>

**For basic information on the current brand used at BC Cancer, see [Chemotherapy Preparation and Stability Chart in Appendix](#).**

### SOLUTION PREPARATION AND COMPATIBILITY:

**For basic information on the current brand used at BC Cancer, see [Chemotherapy Preparation and Stability Chart in Appendix](#).**

#### **Additional information:**

- D5W, hetastarch in sodium chloride (HESPAN®), or solutions containing bicarbonate have the potential to increase the rate of degradation of azacitidine.<sup>4</sup>
- Preparations intended for subcutaneous administration cannot be given by other routes; unique reconstitution and dilution instructions apply to preparations intended for routes other than subcutaneous administration.<sup>11</sup>
- Stability of azacitidine is highly temperature sensitive; reconstituted azacitidine degrades more slowly at cold temperatures.<sup>12,13</sup> Stability may be extended by using a cold diluent for reconstitution or by refrigerating or freezing the reconstituted solution.<sup>13-18</sup>

**Compatibility:** consult detailed reference

### PARENTERAL ADMINISTRATION:

BC Cancer administration guideline noted in **bold, italics**

<b>Subcutaneous</b>	<ul style="list-style-type: none"> <li>• <b>into the upper arm, thigh, or abdomen; rotate sites of injection</b><sup>4</sup></li> <li>• volumes up to and including 4 mL may be injected into a single site; <b>volumes greater than 4 mL</b> are to be injected into <b>two separate sites</b><sup>4,19</sup></li> <li>• using the <b>“air sandwich”</b> technique for subcutaneous administration may reduce the risk and severity of injection site reactions<sup>20</sup></li> </ul>
Intramuscular	no information found
Direct intravenous	no information found
Intermittent infusion	has been used <sup>11,21,22</sup>
Continuous infusion	no information found
Intraperitoneal	no information found
Intrapleural	no information found
Intrathecal	no information found
Intra-arterial	no information found
Intravesical	no information found

### DOSAGE GUIDELINES:

Refer to protocol by which patient is being treated. Numerous dosing schedules exist and depend on disease, response, and concomitant therapy. Guidelines for dosing also include consideration of absolute neutrophil count (ANC). Dosage may be reduced, delayed or discontinued in patients with bone marrow depression due to cytotoxic/radiation therapy or with other toxicities.

#### Adults:

BC Cancer usual dose noted in **bold, italics**

Subcutaneous: Cycle Length:  
**4 weeks**<sup>4,23,24</sup> **75 mg/m<sup>2</sup>** (range 37.5-100 mg/m<sup>2</sup>) **SC once daily for 7 consecutive days starting on day 1**  
 (total dose per cycle 525 mg/m<sup>2</sup> [range 262.5 -700 mg/m<sup>2</sup>])

If a dose is missed during the 7 days of treatment, it should be added to the end of the current dosing cycle.

BC Cancer usual dose noted in ***bold, italics***

Cycle Length:

**4 weeks**.<sup>10,23,24</sup>

If treatment must be interrupted by weekends, alternative dosing schedules that eliminate weekend dosing have been used:

***75 mg/m<sup>2</sup> SC*** (range 37.5-75 mg/m<sup>2</sup>) ***once daily for 5 consecutive days starting on day 1, no treatment on days 6-7, then 75 mg/m<sup>2</sup> SC once daily for 2 consecutive days starting on day 8*** (for a total of 7 days of treatment per cycle given 5 on -2 off -2 on)  
(total dose per cycle 525 mg/m<sup>2</sup> [range 262.5 -525 mg/m<sup>2</sup>])

OR

50 mg/m<sup>2</sup> SC once daily for 5 consecutive days starting on day 1, no treatment on days 6-7, then 50 mg/m<sup>2</sup> SC once daily for 5 consecutive days starting on day 8 (for a total of 10 days of treatment given 5 on -2 off -5 on)  
(total dose per cycle 500 mg/m<sup>2</sup>)

OR

75 mg/m<sup>2</sup> SC once daily for 5 consecutive days starting on day 1  
(total dose per cycle 375 mg/m<sup>2</sup>)

The efficacy of alternate dosing schedules is not known.<sup>10</sup>

<i>Concurrent radiation:</i>	no information found
<i>Dosage in myelosuppression:</i>	modify according to protocol by which patient is being treated; if no guidelines available, refer to Appendix "Dosage Modification for Myelosuppression"
<i>Dosage in renal failure:</i>	no specific modification to starting dose is recommended <sup>4</sup>
<i>Dosage in hepatic failure:</i>	no information found
<i>Dosage in dialysis:</i>	no information found
<b><u>Children:</u></b>	has been used <sup>23</sup>

## REFERENCES:

1. AHFS Drug Information® (database on the Internet). Azacitidine. Lexi-Comp Inc., 13 June 2011. Available at: <http://online.lexi.com>. Accessed 24 October 2011.
2. Celgene Inc. VIDAZA® product monograph. Mississauga, Ontario; 7 July 2011.
3. Lexi-Drugs Online® (database on the Internet). AzaCITidine. Lexi-Comp Inc., 17 October 2011. Available at: <http://online.lexi.com>. Accessed 24 October 2011.
4. Celgene Inc. VIDAZA® product monograph. Mississauga, Ontario; 17 May 2012.
5. Tom Nevill MD. Personal communication. BC Cancer Agency Leukemia/BMT Tumour Group; 11 October 2012.

6. Judith Nyrose. Personal communication. BC Cancer Agency Leukemia/BMT Tumour Group Pharmacist; 6 November 2012.
7. Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. *J Clin Oncol* 2006;24(24):3895-3903.
8. BC Cancer Agency. (SCNAUSEA) Guidelines for Prevention and Treatment of Chemotherapy-induced Nausea and Vomiting in Adults. Vancouver, British Columbia: BC Cancer Agency; 1 Mar 2012.
9. BC Cancer Agency Provincial Systemic Therapy Program. Provincial Systemic Therapy Program Policy III-20: Prevention and Management of Extravasation of Chemotherapy. Vancouver, British Columbia: BC Cancer Agency; 1 February 2012.
10. Lyons RM, Cosgriff TM, Modi SS, et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. *J Clin Oncol* 2009;27(11):1850-1856.
11. Celgene Corporation. VIDAZA® full prescribing information. Summit, NJ, USA; January 2012.
12. Cheung YW, Vishnuvajjala BR, Morris NL, et al. Stability of azacitidine in infusion fluids. *Am J Hosp Pharm* 1984;41(6):1156-1159.
13. den Hartigh J, Brandenburg HC, Vermeij P. Stability of azacitidine in lactated Ringer's injection frozen in polypropylene syringes. *Am J Hosp Pharm* 1989;46(12):2500-2505.
14. Tutino A, Lai M. Cold water reconstitution of Vidaza with subsequent refrigerated storage prolongs drug stability. *Eur J Oncol Pharm* 2011;5(3-4):24-25, 34.
15. Duriez A, Vigneron JH, Zenier HA, et al. Stability of azacitidine suspensions. *Ann Pharmacother* 2011;45(4):546.
16. Walker SE, Charbonneau LF, Law S, et al. Stability of azacitidine in sterile water for injection. *Can J Hosp Pharm* 2012;65(5):352-359.
17. Legeron R, Xuereb F, Djabarouti S, et al. Chemical stability of azacitidine suspensions for injection after cold-chain reconstitution of powder and storage. *Am J Health-Syst Pharm* 2013;70(23):2137-3142.
18. Galloni C, Azzarà V, Loardi G. Extended chemical-physical stability of 25 mg/ml azacitidine suspension. *Eur J Hosp Pharm* 2013;20(Suppl 1):A74-A74 (abstr TCH-016).
19. Celgene Inc. VIDAZA® product monograph. Mississauga, Ontario; 22 March 2018.
20. Murray C, Wereley A, Nixon S, et al. Counselling and adverse event management for patients with myelodysplastic syndromes undergoing azacitidine therapy: a practice standard for Canadian nurses. *CONJ* 2012;22(4):222-227.
21. Martin MG, Walgren RA, Procknow E, et al. A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes. *Am J Hematol* 2009;84:560-564.
22. Marc Demers RN. Personal communication. Medical Information Specialist, Celgene Inc.; 21 March 2012.
23. Lexi-Drugs Online® (database on the Internet). AzaCITIDine. Lexi-Comp Inc., 12 April 2012. Available at: <http://online.lexi.com>. Accessed 12 June 2012.
24. BC Cancer Agency Leukemia/BMT Tumour Group. (ULKMDSA) BCCA Protocol Summary for Therapy of Myelodysplastic Syndrome using Azacitidine. Vancouver, British Columbia: BC Cancer Agency; 1 July 2012.